DSKYF - Merck: Better Times Ahead On Approvals And Outlook
2024-04-02 16:39:37 ET
Summary
- After a forgettable last year, Merck & Co., Inc.'s stock price is up 20% YTD, supported by approvals, a positive outlook for 2024, and an attractive forward P/E.
- Keytruda, the company's top-selling treatment, received approval from the European Commission, and hypertension treatment Winrevair received FDA approval.
- While its collaboration with Daiichi Sankyo and acquisitions reduced the EPS for 2023, Merck expects a turnaround this year, making for an attractive forward P/E compared to its 5y average.
One of the biggest pharmaceutical stocks by market capitalization, Merck & Co., Inc. ( MRK ) has had a good first quarter at the stock markets in 2024. Its price is up by over 20% after a forgettable 2023 that saw it end the year essentially flat, supported by approvals for its treatments as well as its final quarter (Q4 2023) and full-year 2023 results ....
Merck: Better Times Ahead On Approvals And Outlook